Company News...
Abbot Vascular
ABBOTT PARK, Ill. Dec. 22, 2005 – Abbott announced it received Food and Drug Administration (FDA) approval to market its StarClose® Vascular Closure System, a new vessel closure device engineered to enable faster, safe and secure closure and earlier patient mobilization after catheterization.
Read more here...

GE Healthcare Unveils Algorithms That May Help Physicians Predict Risk of Sudden Cardiac Death in Patients
GE’s New Algorithms, When Used Together, May Help Physicians Predict Which Patients Are At Risk For Sudden Cardiac Death; For The First Time, Algorithms Can Be Used In Combination with New Remote, Portable Technology
For more information contact Kristin Binns 262-544-3616 kristin.binns@ge.com

Boston Scientific Announces Agreement to Sell Guidant's Vascular Intervention and Endovascular Businesses to AbbottBoston Scientific to Share Rights to Guidant’s Drug-Eluting Stent Portfolio
Natick, MA (January 8, 2006) – Boston Scientific Corporation (NYSE: BSX) announced today that it has executed a binding definitive agreement with Abbott (NYSE: ABT) under which Abbott will purchase Guidant Corporation’s (NYSE: GDT) vascular intervention and endovascular businesses, assuming completion of Boston Scientific’s proposed acquisition of Guidant (announced in a separate Boston Scientific press release issued today).
Read More Here....

Cordis - Clinical Success and Wordwide Growth of the Cypher Sirolimus Drug Eluting Stent
Read More Here....

Edwards Unveils Ascendra Aortic Heart Valve Replacement System
Surgeons Perform First Beating-Heart, Small-Incision Heart Valve Procedure
IRVINE, Calif., Nov. 29, 2005 -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in heart valve technologies, announced today the successful completion of the first minimal-access, beating-heart surgical procedure for replacing a patient's aortic heart valve. Edwards is planning on developing the Ascendra aortic heart valve replacement system as an additional option for valve surgery.
Read More Here....

|